**Original Research Manuscripts**


Meaningful Declines in Forced Vital Capacity: Analysis of Data from Three Phase 3 Trials in Patients with Idiopathic Pulmonary Fibrosis. Accepted to Thorax 2/15/2016.

Submitted


Reviews


Abstracts


11. Nathan SD, Baseline characteristics of patients enrolled in a prospective study of Riociguat for pulmonary hypertension associated with Idiopathic Interstitial Pneumonia (RISE-IIP Study). Accepted ATS 2016.


15. Nathan SD, Stayrook SA, King C, Weir N, Ahmad S, Shlobin OA, Brown AW. Residual volume-corrected forced vital capacity change: a more accurate indicator of outcomes in IPF? To be accepted to ATS 2016

16. Baughman RP, Nathan SD, Engel PJ, Scholand MB, Barney J, Culver DA. The use of registry for sarcoidosis associated pulmonary hypertension (ReSAPH) in the design of the riociguat for sarcoidosis associated pulmonary hypertension (RioSAPH) clinical trial. Accepted to ATS 2016


20. Rodrigues L, Bui S, Nathan SD, Grant GM. Could infection be a significant factor in IPF? Submitted to ATS 2016


